170 related articles for article (PubMed ID: 8435812)
1. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28.
Epstein BE; Scott CB; Sause WT; Rotman M; Sneed PK; Janjan NA; Davis LW; Selim H; Mohiuddin M; Wasserman TH
Cancer; 1993 Feb; 71(4):1362-7. PubMed ID: 8435812
[TBL] [Abstract][Full Text] [Related]
2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
Murray KJ; Scott C; Greenberg HM; Emami B; Seider M; Vora NL; Olson C; Whitton A; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):571-4. PubMed ID: 9336134
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase.
Chatani M; Matayoshi Y; Masaki N; Inoue T
Strahlenther Onkol; 1994 Mar; 170(3):155-61. PubMed ID: 8160096
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.
Byhardt RW; Pajak TF; Emami B; Herskovic A; Doggett RS; Olsen LA
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):459-68. PubMed ID: 8390420
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
[TBL] [Abstract][Full Text] [Related]
8. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28.
Sause WT; Scott C; Krisch R; Rotman M; Sneed PK; Janjan N; Davis L; Curran W; Choi KN; Selim H
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):653-7. PubMed ID: 8330997
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
11. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
Fu KK; Pajak TF; Marcial VA; Ortiz HG; Rotman M; Asbell SO; Coia LR; Vora NL; Byhardt R; Rubin P
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):577-88. PubMed ID: 7790242
[TBL] [Abstract][Full Text] [Related]
12. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
13. [Radiation therapy for brain metastases from lung carcinoma: the second prospective randomized trial].
Chatani M; Matayoshi Y; Masaki N; Inoue T
Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Dec; 54(14):1380-7. PubMed ID: 7596767
[TBL] [Abstract][Full Text] [Related]
14. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Perez CA
Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):7-12. PubMed ID: 1847128
[TBL] [Abstract][Full Text] [Related]
15. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.
Cox JD; Pajak TF; Marcial VA; Coia L; Mohiuddin M; Fu KK; Selim H; Rubin P; Ortiz H
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1191-5. PubMed ID: 2045293
[TBL] [Abstract][Full Text] [Related]
16. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.
Cox JD; Pajak TF; Marcial VA; Hanks GE; Mohiuddin M; Fu KK; Byhardt RW; Rubin P
Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):515-21. PubMed ID: 2180866
[TBL] [Abstract][Full Text] [Related]
17. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.
Le Péchoux C; Dunant A; Senan S; Wolfson A; Quoix E; Faivre-Finn C; Ciuleanu T; Arriagada R; Jones R; Wanders R; Lerouge D; Laplanche A;
Lancet Oncol; 2009 May; 10(5):467-74. PubMed ID: 19386548
[TBL] [Abstract][Full Text] [Related]
18. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of short-course accelerated whole brain radiation therapy for multiple brain metastases.
Caravatta L; Deodato F; Ferro M; Macchia G; Massaccesi M; Cilla S; Padula GD; Mignogna S; Tambaro R; Carrozza F; Flocco M; Cantore G; Scapati A; Buwenge M; Sticca G; Valentini V; Cellini N; Morganti AG
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e463-8. PubMed ID: 22909415
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
